Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Abstract Text:

Julie M Cunningham,Scott J Hebbring,Shannon K McDonnell,Mine S Cicek,G Bryce Christensen,Liang Wang,Steven J Jacobsen,James R Cerhan,Michael L Blute,Daniel J Schaid,Stephen N Thibodeau,

Previous studies suggest that enzymes involved in the androgen metabolic pathway are susceptibility factors for prostate cancer. Estrogen metabolites functioning as genotoxins have also been proposed as risk factors. In this study, we systematically tested the hypothesis that common genetic variations for those enzymes involved in the androgen and estrogen metabolic pathways increase risk for sporadic and familial prostate cancer. From these two pathways, 46 polymorphisms (34 single nucleotide polymorphisms, 10 short tandem repeat polymorphisms, and 2 null alleles) in 25 genes were tested for possible associations. Those genes tested included PRL, LHB, CYP11A1, HSD3B1, HSD3B2, HSD17B2, CYP17, SRD5A2, AKR1C3, UGT2B15, AR, SHBG, and KLK3 from the androgen pathway and CYP19, HSD17B1, CYP1A1, CYP1A2, CYP1B1, COMT, GSTP1, GSTT1, GSTM1, NQO1, ESR1, and ESR2 from the estrogen pathway. A case-control study design was used with two sets of cases: familial cases with a strong prostate cancer family history (n = 438 from 178 families) and sporadic cases with a negative prostate cancer family history (n = 499). The controls (n = 493) were derived from a population-based collection. Our results provide suggestive findings for an association with either familial or sporadic prostate cancer with polymorphisms in four genes: AKR1C3, HSD17B1, NQO1, and GSTT1. Additional suggestive findings for an association with clinical variables (disease stage, grade, and/or node status) were observed for single nucleotide polymorphisms in eight genes: HSD3B2, SRD5A2, SHBG, ESR1, CYP1A1, CYP1B1, GSTT1, and NQO1. However, none of the findings were statistically significant after appropriate corrections for multiple comparisons. Given that the point estimates for the odds ratio for each of these polymorphisms are <2.0, much larger sample sizes will be required for confirmation.

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Publishing Authors By Initials

JM Cunningham,SJ Hebbring,SK McDonnell,MS Cicek,GB Christensen,L Wang,SJ Jacobsen,JR Cerhan,ML Blute,DJ Schaid,SN Thibodeau,

For similar genetic phenomena: variation (genetics) research abstracts see: genetic phenomena: variation (genetics) research

PUBMED ID PMID:

MEDLINE DATE:

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cancer epidemiology, biomarkers & prevention : a p

VOLUME: 16

Page Numbers: 969-78

Journal Abbreviation: Cancer Epidemiol. Biomarkers P

ISSN: 1055-9965

DAY: 3

MONTH: May

YEAR: 2007

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9200608

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Keywords Mesh Terms:

KEYWORDS: Variation (Genetics)

MESH TERMS: genetics

Chemical & Substance for Abstract: Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Information

Substance Name: Estrogens

Registry Number: 0

Grant and Affiliation Information for Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.

AFFILIATION: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA92049

ACRONYM: CA

MEDLINETA: Cancer Epidemiol Biomarkers Pr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer Related Publications

• Ascending the learning curve--MSI testing experience of a six-laboratory consortium.
• Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
• Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb.
• Frequency of Defective DNA Mismatch Repair in Colorectal Cancer among the Alaska Native People.
• Higher frequency of diploidy in young-onset microsatellite-stable colorectal cancer.
• Human SULT1A1 gene: copy number differences and functional implications.
• Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer.
• Role of friction and tangential force variation in the subjective scaling of tactile roughness.
• Testing genetic linkage with relative pairs and covariates by quasi-likelihood score statistics.
• Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.